

SEP - 1 1999

## Summary of Safety and Effectiveness

Submitter: Biomet, Inc.  
P.O. Box 587  
Airport Industrial Park  
Warsaw, Indiana 46581-0587

Contact Person: Michelle L. McKinley

Product Code: 87 HWC

Device Name: ReUnite™ Screws

The ReUnite™ Bone Screws are indicated for use in the presence of appropriate immobilization in the following procedures:

1. correction of hallux valgus (bunion)
2. repair of metacarpal and phalangeal fusion and fracture

The ReUnite™ Screws are made of bioresorbable and biocompatible polymer that have been used in surgical procedures for a number of years. LactoSorb® resorbable copolymer is synthetic polyester derived from lactic and glycolic acids. Polylactic/polyglycolic (PLLA/PGA) acid copolymer degrades and resorbs IN VIVO by hydrolysis to lactic and glycolic acids, which are then metabolized by the body. The LactoSorb® material has been found to be biocompatible in both soft and hard bone tissues.

The effectiveness of the resorbable screws was determined by mechanical testing. These screws are as strong or stronger than the LactoSorb® Bone Pin. The device completely resorbs in approximately 12 months IN VIVO eliminating the need for long-term removal.

000004



SEP - 1 1999

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Michelle L. McKinley  
Regulatory Specialist  
Biomet Incorporated  
P.O. Box 587  
Warsaw, Indiana 46581-0587

Re: K992301

Trade Name: ReUnit<sup>TM</sup> Screw  
Regulatory Class: II  
Product Code: HWC and MAI  
Dated: July 6, 1999  
Received: July 8, 1999

Dear Ms. McKinley:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 – Ms. Michelle L. McKinley

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "C. Witten", is written over the typed name. To the left of the signature is a small, stylized handwritten mark that resembles the letter "f".

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General and  
Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(K) NUMBER (IF KNOWN): K992301

DEVICE NAME: ReUnite™ Screw

INDICATIONS FOR USE:

The ReUnite™ Screws are indicated for use in the presence of appropriate immobilization in the following procedures:

1. correction of hallux valgus (bunion)
2. repair of metacarpal and phalangeal fusion and fractures

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED.)


---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X  
(Per 21 CFR 801.109)

OR

Over-the-Counter Use \_\_\_\_\_  
(Optional Format 1-2-96)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of General Restorative Devices  
510(k) Number K992301

000003